SEI Investments Co. has disclosed its latest holdings in a 13F-HR filing, revealing a diverse portfolio that underscores its strategic investment approach. This filing is significant as it provides insights into the company's investment strategies and highlights trends within the security brokers and dealers industry.

As of September 30, 2026, SEI Investments reported a total value of approximately $112.6 billion across 6,069 positions. The filing, dated November 10, 2026, showcases the firm’s active management style and its ability to adapt to market conditions.

Background

SEI Investments Co., incorporated in Pennsylvania, operates in the security brokers, dealers, and flotation companies sector, classified under SIC code 6211. The firm is listed on the Nasdaq under the ticker symbol SEIC. SEI is recognized for providing investment management services and technology solutions, catering to various clients, including financial institutions and individual investors.

Recent filings from SEI include a Schedule 13G/A and multiple Form 4 submissions on November 12, 2026, indicating ongoing activity in the firm’s investment management practices.

What the Filing Says

The 13F-HR filing details SEI’s holdings across various sectors, with significant investments noted in companies like 10X Genomics and Abbott Laboratories. The filing indicates that SEI has a diversified investment strategy, focusing on growth potential within its portfolio.

Impact

This filing may affect various stakeholders, including investors, analysts, and competitors in the security brokers and dealers sector. By revealing its investment positions, SEI provides insights that could influence market perceptions and strategies among its peers.

What’s Next

The filing does not specify what happens next for SEI Investments Co., but it sets the stage for future disclosures and potential shifts in investment strategy as the market evolves.

Source: SEC Accession Number 0000350894-26-000059